Company Overview and News
2018-09-15 seekingalpha - 3
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
DOVA GIS TXN CAT AZO TWX RCL OPRF MAS HABT SHAK SUM BOX SONC RCII ABBV USCR FOX REGN BAC SQ DFS TRV COF-P WK BX JACK SYF AIG WEN ALL IDA KNSA NVS ABBV MSFT FL ZOES PFE ADS FOXA MLM JD NIO ATH DRI CX PYPL AXP MCO JBHT BRO EXP USB BAC COF-D COF-C COF-F HIG AAPL VMC TSG ORCL DEO MCD BMY RRGB WBC C CMCSA O THO MA M COF FDX NAVG HUM SNY RHT DSKE JPM IBOC MU DHR
It has been fifteen years since I covered Nike stock way back during my IR days. The retail space is such a darling in the early 2000s – an era of pop culture and the turbulent times of the 911 terror.
BCS DB NKE FL
It’s been a great start to the week for Foot Locker (NYSE:FL). Keep in mind that the shares have been in a downtrend during the past three months. But as of Monday, Foot Locker stock jumped by 5%.
WFC WFCNP WMT TGT AMZN NKE KSS FL
Nike Inc. was upgraded to buy from hold at Canaccord Genuity, as the brand undergoes a turnaround fueled by innovation, improved customer experience, and more controlled distribution of the Jordan basketball brand, analysts say.
WFC WFCNP NKE FL
(Reuters) - Britain’s JD Sports (JD.L) promised on Tuesday to back up its purchase of U.S. chain Finish Line by investing 200 million pounds ($260.7 million) over the next five years after overseas growth helped fuel a 19 percent rise in first-half earnings.
HL HRGLY HRGLF FINL FL
2018-09-10 247wallst - 2
Stocks were indicated to open higher on Monday after a choppy prior week. Investors have seen less upside when they have bought the market pullbacks than in prior years, and investors need to be considering how they want their investments positioned for the rest of 2018.
WFCNP ATHTF STZ.B NKE AMZN AEP MS AKAM GWP OSTK WFC NBIX STZ ANTM HL TRI FL UNH ANTX
Foot Locker Inc. FL, +4.60% shares are up 2.7% in Monday premarket trading after it was upgraded to outperform from market perform at Wells Fargo on improvements at Nike Inc. NKE, +2.35% Wells Fargo raised its price target to $58 from $50. Analysts attributes Foot Locker's issues over the past 18 months to problems with the Nike brand. Current controversy over its choice of Colin Kaepernick as a spokesperson aside, Wells Fargo highlights merchandise innovations like the Air Max 270, and the diminished headwinds from the Jordan basketball brand and the European marketplace.
WFC WFCNP NKE FL
Nike (NKE - Free Report) saw its stock price pop in morning trading Friday even as controversy surrounding its new advertising campaign starring Colin Kaepernick remains national news. The question for investors is should they consider buying Nike stock right now as the NFL season begins?
JD FB NKE ADDYY FL
On today’s episode of the Tech Talk Tuesday podcast, Ryan McQueeney recaps a historic day for Amazon (AMZN - Free Report) which saw the e-commerce behemoth reach the $1 trillion market cap threshold and launch Hindi language support in India.
MSFT NYTAB FL WMT
Welcome to the latest episode of the Full-Court Finance podcast from Zacks Investment Research where Associate Stock Strategist Ben Rains breaks down the big business behind the NFL as the league’s falling TV ratings and continued controversy take center stage once again. But is the NFL really in that bad of a spot at the moment?
CHTR NKE PEP NFLX MSFT FDX FL ATVI
Welcome to the August edition of “Monthly Dividend Stock Discounts”. Each month, I create a list of US dividend stocks with more than 5% discount in the last month. The purpose is to identify potential bargains for dividend investors. Yet, as you surely know, a dropping stock price typically means one of two things: either it’s an opportunity to get more bang for your buck, or it is a warning sign that the company faces serious headwinds and future dividends may be in trouble.
TDS AVGO FL
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to FL / Foot Locker, Inc. on message board site Silicon Investor.
as of ET